Looking forward: Z160 success and a Snutch Nobel Prize
Dr. Snutch, simply Terry to the Zalicus faithful, pioneered cone snail toxin mechanism characterization in the mammalian nervous system. He has a legacy of articles many labeled as "Classics" by Science magazine. He really has the foundation for a Nobel Prize here, and Z160 could be a big part of this potential prestigious recognition.
For the investor, a successful phase 2a would likely put ZLCS back on the NASDAQ at a PPS of around what? Anybody have any idea what the POTENTIAL of a pain medicine that can replace addictive opioids might demand at the phase 2a development stage? I am guessing what, 5 PPS?
Of course failure is always an option, a real option, but there is no need to guess the PPS should this happen. Odds according to Jason Napodano are 20% probability of success while CFO Justin Renz says 50-50% according to Garrett.